Human CD27 Ligand/TNFSF7 Antibody
R&D Systems, part of Bio-Techne | Catalog # AF2738
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, Flow Cytometry, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Product Specifications
Immunogen
Mouse myeloma cell line NS0-derived recombinant human CD27 Ligand/TNFSF7
Gln45-Pro193
Accession # AAA36175
Gln45-Pro193
Accession # AAA36175
Specificity
Detects human CD27 Ligand in direct ELISAs and Western blots. In direct ELISAs, approximately 10% cross-reactivity with recombinant mouse CD27 Ligand and recombinant human (rh) CD30 Ligand is observed, and less than 1% cross-reactivity with rhCD40 Ligand is observed.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Scientific Data Images for Human CD27 Ligand/TNFSF7 Antibody
Detection of Human CD27 Ligand/TNFSF7 by Western Blot.
Western blot shows lysates of THP-1 human acute monocytic leukemia cell line. PVDF membrane was probed with 1 µg/mL of Human CD27 Ligand/TNFSF7 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2738) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for CD27 Ligand/TNFSF7 at approximately 30 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.
Detection of CD27 Ligand/TNFSF7 in Raji Human Cell Line by Flow Cytometry.
Raji human Burkitt's lymphoma cell line was stained with Human CD27 Ligand/TNFSF7 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2738, filled histogram) or control antibody (Catalog # AB-108-C, open histogram), followed by Phycoerythrin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0107).
Detection of CD27Ligand/TNFSF7 in HEK293 Human Cell Line Transfected with Human CD27 Ligand/TNFSF7 by Flow Cytometry.
HEK293 human embryonic kidney cell line transfected with human CD27 Ligand/TNFSF7 (filled histogram) or irrelevant protein (open histogram) was stained with Mouse Anti-Human CD27 Ligand/TNFSF7 Monoclonal Antibody (Catalog # AF2738) followed by anti-goat PE-conjugated secondary antibody (F0107). Staining was performed using our Staining Membrane-associated Proteins protocol.Applications for Human CD27 Ligand/TNFSF7 Antibody
Application
Recommended Usage
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
Flow Cytometry
0.25 µg/106 cells
Sample: Raji human Burkitt's lymphoma cell line and HEK293 human embryonic kidney cell line transfected with human CD27 Ligand/TNFSF7
Sample: Raji human Burkitt's lymphoma cell line and HEK293 human embryonic kidney cell line transfected with human CD27 Ligand/TNFSF7
Western Blot
1 µg/mL
Sample: THP-1 human acute monocytic leukemia cell line
Sample: THP-1 human acute monocytic leukemia cell line
Reviewed Applications
Read 1 review rated 5 using AF2738 in the following applications:
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CD27 Ligand/TNFSF7
Alternate Names
CD70, TNFSF7
Gene Symbol
CD70
UniProt
Additional CD27 Ligand/TNFSF7 Products
Product Documents for Human CD27 Ligand/TNFSF7 Antibody
Product Specific Notices for Human CD27 Ligand/TNFSF7 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...
Loading...